首页> 外文会议>Society for Biomaterials annual meeting and exposition >Antimicrobial Activities of Conventional and Novel Antimicrobial Agents against S. aureus Biofilms
【24h】

Antimicrobial Activities of Conventional and Novel Antimicrobial Agents against S. aureus Biofilms

机译:常规和新型抗微生物剂对抗金黄色菌生物膜的抗菌活性

获取原文

摘要

Biofilms are problematic in the pathogenesis of PJI, as they are difficult to treat and current standards of treatment, such as antibiotics and surgical techniques, may have limitations in terms of efficacy and morbidity. Therefore, there is a need for new antimicrobial agents to treat these infections. Our findings reveal that AgNPs significantly reduced the number of biofilm CFUs. The efficacy of AgNPs toward inhibiting biofilms was found to be better than some commonly used antibiotics, like vancomycin and cefazolin, at similar concentrations. Rifampin was found to be the most efficacious of all treatments applied, however rifampin may not be practical to use as it may induce antibiotic resistance and carry unwanted side effects. One limitation of the study is the composition of the biofilm in our study as they were only grown for 24 h and may not demonstrate the maturity of biofilms seen in chronic clinical infections. Future studies will be aimed at treating more established and heterogeneous biofilms in animal models.
机译:生物膜是在PJI的发病机制有问题的,因为它们难以治疗和治疗的现行标准,如抗生素和手术技巧,在疗效和发病率方面的限制。因此,需要新的抗菌药物来治疗这些感染。我们的研究结果表明的AgNPs显著减少生物膜CFU的数量。朝向抑制生物膜的AgNPs的功效被认为是要比较好一些常用的抗生素,如万古霉素和头孢唑啉,在相似浓度。利福平被发现是最有效的所有处理施加然而利福平可能是不实际使用,因为它可能引起抗生素抗性并携带不希望的副作用。这项研究的一个限制是在我们的研究生物膜的组成,因为它们只生长24个小时,可以不显示在慢性感染,临床上可见生物膜的成熟。未来的研究将着眼于在动物模型中治疗更成熟的,异构的生物膜。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号